Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel supra-annular plane to predict TAVI prosthesis anchoring in raphe-type bicuspid aortic valve disease: the LIRA plane.
Iannopollo G, Romano V, Buzzatti N, De Backer O, Søndergaard L, Merkely B, Prendergast BD, Giannini F, Colombo A, Latib A, Granada JF, Chieffo A, Montorfano M. Iannopollo G, et al. Among authors: granada jf. EuroIntervention. 2020 Jun 25;16(3):259-261. doi: 10.4244/EIJ-D-19-00951. EuroIntervention. 2020. PMID: 31659989 Free article. No abstract available.
First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial.
Chieffo A, Khawaja SA, Latib A, Vesga B, Moncada M, Delgado JA, Fonseca J, Testa L, Esposito G, Ferrone M, Cortese B, Maehara A, Granada JF, Colombo A; Collaborators. Chieffo A, et al. Among authors: granada jf. EuroIntervention. 2020 Jun 12;16(2):e133-e140. doi: 10.4244/EIJ-D-19-00600. EuroIntervention. 2020. PMID: 32149709 Free article. Clinical Trial.
First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study.
Chieffo A, Khawaja SA, Vesga B, Hernandez H, Moncada M, Delgado JA, Esposito G, Ferrone M, Dager A, Arana C, Stabile E, Meliga E, De Benedictis M, Montorfano M, Latib A, Fonseca J, Gomez G, Tamburino C, Tarantini G, La Manna A, Maehara A, Granada JF, Colombo A. Chieffo A, et al. Among authors: granada jf. Int J Cardiol. 2020 Dec 15;321:48-53. doi: 10.1016/j.ijcard.2020.08.014. Epub 2020 Aug 15. Int J Cardiol. 2020. PMID: 32810542
RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results.
Ferrone M, Chieffo A, Khawaja SA, Moncada M, Colombo A, Latib A, Esposito G, Stabile E, Avvedimento M, Bedogni F, Testa L, Delgado JA, Arana C, Vesga B, Cortese B, Mahera A, Granada JF. Ferrone M, et al. Among authors: granada jf. Circ Cardiovasc Interv. 2021 May;14(5):e010013. doi: 10.1161/CIRCINTERVENTIONS.120.010013. Epub 2021 May 18. Circ Cardiovasc Interv. 2021. PMID: 34003665 No abstract available.
Impact of inferior vena cava entry characteristics on tricuspid annular access during transcatheter interventions.
Ranard LS, Vahl TP, Chung CJ, Sadri S, Khalique OK, Hamid N, Nazif T, George I, Ng V, Patel A, Rezende CP, Reisman M, Latib A, Hausleiter J, Sorajja P, Bapat VN, Tang GHL, Davidson CJ, Zahr F, Makkar R, Fam NP, Granada JF, Leon MB, Hahn RT, Kodali S. Ranard LS, et al. Among authors: granada jf. Catheter Cardiovasc Interv. 2022 Mar;99(4):1268-1276. doi: 10.1002/ccd.30048. Epub 2022 Jan 27. Catheter Cardiovasc Interv. 2022. PMID: 35084803
219 results